Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.
For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.
To maintain a collaborative, "no lanes" culture while scaling, Coya's CEO prioritizes hiring individuals with a strong sense of curiosity and a willingness to learn. This strategy counteracts the silo-building tendency of hiring narrow experts who may be less adaptable or open to cross-functional input.
The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.
Coya Therapeutics' CEO frames their ongoing ALS trial as the "biggest executional milestone" in the company's history. This highlights the reality for emerging biotechs: success or failure often boils down to the disciplined execution and eventual readout of one transformative clinical study that can validate their entire platform.
A fully virtual model works well for companies like Coya Therapeutics that hire experienced, self-motivated professionals. However, the CEO acknowledges this model may be detrimental for early-career employees who need the in-person mentorship and learning-by-osmosis that an office environment provides, posing a future scaling challenge.